Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
150 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Teva Pharmaceutical Industries Limited - Product Pipeline Review - 2016', provides an overview of the Teva Pharmaceutical Industries Limited's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Teva Pharmaceutical Industries Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Teva Pharmaceutical Industries Limited - The report provides overview of Teva Pharmaceutical Industries Limited including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Teva Pharmaceutical Industries Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Teva Pharmaceutical Industries Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to Buy - Evaluate Teva Pharmaceutical Industries Limited's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Teva Pharmaceutical Industries Limited - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Teva Pharmaceutical Industries Limited's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Teva Pharmaceutical Industries Limited Snapshot 6 Teva Pharmaceutical Industries Limited Overview 6 Key Information 6 Key Facts 6 Teva Pharmaceutical Industries Limited - Research and Development Overview 7 Key Therapeutic Areas 7 Teva Pharmaceutical Industries Limited - Pipeline Review 12 Pipeline Products by Stage of Development 12 Pipeline Products - Monotherapy 13 Pipeline Products - Combination Treatment Modalities 14 Pipeline Products - Partnered Products 15 Pipeline Products - Out-Licensed Products 17 Teva Pharmaceutical Industries Limited - Pipeline Products Glance 19 Teva Pharmaceutical Industries Limited - Late Stage Pipeline Products 19 Teva Pharmaceutical Industries Limited - Clinical Stage Pipeline Products 22 Teva Pharmaceutical Industries Limited - Early Stage Pipeline Products 24 Teva Pharmaceutical Industries Limited - Unknown Stage Pipeline Products 26 Teva Pharmaceutical Industries Limited - Drug Profiles 27 (fluticasone propionate + salmeterol xinafoate) 27 deutetrabenazine ER 28 hydrocodone bitartrate ER 30 laquinimod sodium 32 reslizumab 35 omacetaxine mepesuccinate 37 (acetaminophen + hydrocodone bitartarate) IR 40 armodafinil 41 beclomethasone dipropionate 43 bendamustine hydrochloride 45 fluticasone propionate 48 rasagiline mesylate 49 TEV-48125 50 funapide 51 pridopidine hydrochloride 52 TV-1380 54 (acetaminophen + oxycodone hydrochloride) IR 55 (fluticasone propionate + salmeterol xinafoate) MDI 56 CEP-37440 57 glatiramer acetate 58 SD-560 60 TEV-48107 61 TEV-90110 62 TEV-90111 63 TEV-90112 64 TEV-90113 65 TV-44664 66 atropine sulfate 67 CEP-11981 68 CEP-28122 69 CEP-33779 70 Drug for Undisclosed Indication 71 NIB-2 72 NP-201 73 NP-202 74 Recombinant Protein to Inhibit IL-17A for Psoriasis 75 Recombinant Protein to Target CD38 for Multiple Myeloma 76 SD-1077 77 Small Molecule 2 to Antagonize 5-HT6 for CNS Disorders 78 Small Molecule to Antagonize NMDA Receptor for Undisclosed Indication 79 Small Molecule to Inhibit CGRP for Migraine 80 Small Molecules to Inhibit DAT for Sleep Disorders 81 (acetaminophen + immediate release opioid 1) 82 (acetaminophen + immediate release opioid 2) 83 AD-3 84 AD-4 85 Fixed Dose Combination 3 for HIV 86 Fixed Dose Combination 4 for HIV 87 Small Molecule 1 to Antagonize 5-HT6 Receptor for CNS Disorders 88 Small Molecule to Inhibit PARP-1 89 Drug for Dependence 90 Drug for Parkinson's Disease 91 risperidone LAI 92 Teva Pharmaceutical Industries Limited - Pipeline Analysis 93 Teva Pharmaceutical Industries Limited - Pipeline Products by Target 93 Teva Pharmaceutical Industries Limited - Pipeline Products by Route of Administration 98 Teva Pharmaceutical Industries Limited - Pipeline Products by Molecule Type 99 Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action 100 Teva Pharmaceutical Industries Limited - Recent Pipeline Updates 103 Teva Pharmaceutical Industries Limited - Dormant Projects 128 Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products 131 Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products 131 Discontinued Pipeline Product Profiles 131 Teva Pharmaceutical Industries Limited - Company Statement 134 Teva Pharmaceutical Industries Limited - Locations And Subsidiaries 137 Head Office 137 Other Locations & Subsidiaries 137 Appendix 145 Methodology 145 Coverage 145 Secondary Research 145 Primary Research 145 Expert Panel Validation 145 Contact Us 145 Disclaimer 146
List of Tables Teva Pharmaceutical Industries Limited, Key Information 10 Teva Pharmaceutical Industries Limited, Key Facts 10 Teva Pharmaceutical Industries Limited - Pipeline by Indication, 2016 13 Teva Pharmaceutical Industries Limited - Pipeline by Stage of Development, 2016 16 Teva Pharmaceutical Industries Limited - Monotherapy Products in Pipeline, 2016 17 Teva Pharmaceutical Industries Limited - Combination Treatment Modalities in Pipeline, 2016 18 Teva Pharmaceutical Industries Limited - Partnered Products in Pipeline, 2016 19 Teva Pharmaceutical Industries Limited - Partnered Products/ Combination Treatment Modalities, 2016 20 Teva Pharmaceutical Industries Limited - Out-Licensed Products in Pipeline, 2016 21 Teva Pharmaceutical Industries Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016 22 Teva Pharmaceutical Industries Limited - Pre-Registration, 2016 23 Teva Pharmaceutical Industries Limited - Filing rejected/Withdrawn, 2016 24 Teva Pharmaceutical Industries Limited - Phase III, 2016 25 Teva Pharmaceutical Industries Limited - Phase II, 2016 26 Teva Pharmaceutical Industries Limited - Phase I, 2016 27 Teva Pharmaceutical Industries Limited - Preclinical, 2016 28 Teva Pharmaceutical Industries Limited - Discovery, 2016 29 Teva Pharmaceutical Industries Limited - Unknown, 2016 30 Teva Pharmaceutical Industries Limited - Pipeline by Target, 2016 97 Teva Pharmaceutical Industries Limited - Pipeline by Route of Administration, 2016 102 Teva Pharmaceutical Industries Limited - Pipeline by Molecule Type, 2016 103 Teva Pharmaceutical Industries Limited - Pipeline Products by Mechanism of Action, 2016 104 Teva Pharmaceutical Industries Limited - Recent Pipeline Updates, 2016 107 Teva Pharmaceutical Industries Limited - Dormant Developmental Projects,2016 132 Teva Pharmaceutical Industries Limited - Discontinued Pipeline Products, 2016 135 Teva Pharmaceutical Industries Limited, Other Locations 141 Teva Pharmaceutical Industries Limited, Subsidiaries 142
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.